drugset / Trial / NCT05821738
Avapritinib in CBF-AML With KIT Mutations
NaSingle-groupOpen-labelTreatment
Summary
AML with t(8; 21)(q22; q22) or inv(16)(p13; q22)/t(16; 16)(p13; q22) is known as CBF-AML. KIT mutations are common in CBF-AML, which have a worse prognosis.This study is aimed to evaluate the efficacy of Avapritinib, an highly specific inhibitor of the KIT gene, in CBF-AML with KIT mutations.
Timeline
- Start
- 2022-06-01
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avapritinib | Small molecule | 100 mg | Oral |
| Subject | Avapritinib | Small molecule | 300 mg | Oral |